Agenus Inc. (AGEN) Q3 2024 Earnings Call

Investor webinar replay

Replay transcript excerpt

Good morning and welcome to Agenis' third quarter 2024 conference call and webcast. All participants will be in a listen-only mode until the question and answer session. Please note, this event is being recorded. If anyone has any objections, you may disconnect at this time. I would now like to turn the conference over to Alexa Buffa from Agenis Corporate Communications. Alexa, please go ahead. Thank you, Operator, and thank you all for joining us today. Today's call is being webcast and will be available on our website for reply. I'd like to remind you that this call will include forward-looking statements, including statements regarding our clinical development, regulatory and commercial plans, and timelines, as well as timelines for data releases and partnership opportunities, among other updates. These statements are subject to risks and uncertainties, and we refer you to our SEC filings available on our website for more details on these risks. Joining me today are Dr. Garrow Arman, Chairman and Chief Executive Officer, Dr. Robin Taylor, Chief Commercial Officer, and Christine Klaskin, Vice President of Finance. Dr. Stephen O'Day, Chief Medical Officer, will be participating in the question and answer session. Now I'd like to turn the call over to Garrow to highlight our progress in the third quarter. Thank you, Alexa, and good morning, everyone, and thank you all for joining us today. At Agenis, we are driven by the belief that we can redefine what is possible in cancer treatment. This belief is embodied in the progress we've made with Buc-Val. Buc-Val is showing unprecedented results in cancers that have resisted all previous therapies, as well as in patients with earlier stages of disease who face morbidities associated with conventional treatment options, suc...